I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

ASNR 2023

-
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features

Personalised Healthcare
Apr 29 / Roche and Genentech
GRADUATE I and II: Imaging Findings From Two Phase III trials of Subcutaneous Gantenerumab in Early Alzheimer’s Disease
The GRADUATE I and II studies assessing the efficacy and safety of gantenerumab in early AD included amyloid and tau PET substudies and volumetric magnetic resonance imaging measures to investigate the effects of gantenerumab treatment on these imaging biomarkers in participants. These findings provide further insights into the effects of subcutaneous gantenerumab on amyloid and tau load, and regional brain volume in early AD.

Sign up or login to unlock the full suite of MEDICALLY features

Personalised Healthcare
Apr 29 / Roche and Genentech
Baseline risk factors for developing ARIA-E from the SCarlet RoAD and Marguerite RoAD open-label extension studies
Data from the SCarlet RoAD and Marguerite RoAD open-label extensions were used to identify potential baseline risk factors for the occurrence of ARIA-E under gantenerumab treatment. APOE ε4 carrier status, in particular homozygous status, and microhemorrhage presence were identified as independent, nonmodifiable, and cumulative baseline risk factors for ARIA-E.